These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25779099)

  • 1. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.
    Li M; Yu T; Hu YF
    Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Biomarkers on Personalized Medicine.
    Carrigan P; Krahn T
    Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical consideration and challenges in bridging study of personalized medicine.
    Li M
    J Biopharm Stat; 2015; 25(3):397-407. PubMed ID: 24897254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The relevance of biomarkers for personalised medicine].
    Großhennig A; Benda N; Koch A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1480-8. PubMed ID: 24084852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
    Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
    Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
    Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
    Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
    Cowling T; Boucher M
    Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Companion diagnostic testing for targeted cancer therapies: an overview.
    Fan YS
    Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics.
    Batrla R; Jordan BW
    Ann N Y Acad Sci; 2015 Jun; 1346(1):71-80. PubMed ID: 25866164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics.
    Huckle D
    Expert Rev Mol Diagn; 2015 Jun; 15(6):815-27. PubMed ID: 25990929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical evaluation of drug efficacy for bridging study in companion diagnostic test trials.
    Bu Y; Zhou XH
    J Biopharm Stat; 2016; 26(6):1118-1124. PubMed ID: 27649095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
    Vanitallie TB
    Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical issues on the diagnostic multivariate index assay for targeted clinical trials.
    Liu JP; Chow SC
    J Biopharm Stat; 2008; 18(1):167-82. PubMed ID: 18161547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A visualization method measuring the performance of biomarkers for guiding treatment decisions.
    Yang H; Tang R; Hale M; Huang J
    Pharm Stat; 2016; 15(2):152-64. PubMed ID: 26632104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.